MaaT013: Positive Topline Phase 3 results

See more

Enhancing Survival Through Innovative Immune Modulation

We are a clinical-stage microbiome therapeutics company
aiming to improve survival in cancer.

Our strengths

A full ecosystem approach

Oncology focused

AI-Powered Drug Development

cGMP Versatile Manufacturing Capacities

Latest News

March 18, 2025

March 18, 2025: MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease

March 11, 2025

March 11, 2025: MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013

February 24, 2025

February 20, 2025: Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations – Microbiome Times

Like what you see? See more posts

Our upcoming events

Event
February 11, 2025

BIO-Europe Spring

• March 17-19, 2025 – BIO-Europe Spring, Milan, Italy
MaaT Pharma
Event
February 11, 2025

Microbiome Times Forum

• March 18-19, 2025 – Microbiome Times Partnering Forum
MaaT Pharma
Event
February 11, 2025

EBMT – 51st Annual Meeting

• March 30 to April 2, 2025 – 51st Annual Meeting of the EBMT
MaaT Pharma

Join the MaaT Pharma adventure!

Bring your talents, your passion and join an inclusive, creative, and multidisciplinary team. We aim to leverage the potential of microbiome to improve the treatment of patients with cancer.

Learn more about our values, our environment and see what we have to offer to you!

Careers